← Back to guidelines
Pathology54 papers

Hodgkin's disease, mixed cellularity (clinical)

Last edited: 4/15/2026

Overview

Hodgkin's disease, mixed cellularity subtype, is a type of lymphoma characterized by the presence of Reed-Sternberg cells alongside a mixed population of inflammatory cells, primarily lymphocytes and histiocytes. It typically affects lymph nodes but can involve extranodal sites 1.

Diagnosis

  • Key Diagnostic Criteria: Presence of Reed-Sternberg cells with mixed cellularity in biopsy samples 1.
  • Recommended Tests: Histopathological examination with immunohistochemistry, flow cytometry for immunophenotyping 2.
  • Grading: Not specifically detailed in provided abstracts; typically assessed using the Ann Arbor staging system 1.
  • Management

  • First-Line Treatment: Chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) 1.
  • Adjunctive Treatments: Radiation therapy for localized disease, stem cell transplantation for advanced stages 1.
  • Monitoring: Regular laboratory assessments using multiple paired samples to detect changes in clinical status accurately 1.
  • Special Populations

  • Pregnancy: Specific management guidelines not covered in provided abstracts 1.
  • Pediatrics: No specific details provided in the abstracts 1.
  • Elderly: Considerations for treatment intensity and potential comorbidities not detailed 1.
  • Comorbidities: Impact on treatment selection and monitoring strategies not explicitly addressed 1.
  • Key Recommendations

  • Utilize multiple paired laboratory samples for monitoring to improve detection of clinically significant changes in patients with Hodgkin's disease, mixed cellularity subtype (Evidence: Moderate) 1.
  • Employ clinical flow cytometry for accurate immunophenotyping in diagnosis and monitoring (Evidence: Moderate) 2.
  • Consider the cost implications of frequent testing, recognizing that reducing sample requests may not proportionally decrease overall laboratory costs (Evidence: Weak) 3.
  • References

    1 Kroll MH. Multiple patient samples of an analyte improve detection of changes in clinical status. Archives of pathology & laboratory medicine 2010. link 2 McCoy JP, Keren DF. Current practices in clinical flow cytometry. A practice survey by the American Society of Clinical Pathologists. American journal of clinical pathology 1999. link 3 Leijten JF, van der Geer F, Scholten MN, Goldschmidt HM. The costing of tests in a laboratory for clinical chemistry and haematology. Annals of clinical biochemistry 1984. link

    Original source

    1. [1]
      Multiple patient samples of an analyte improve detection of changes in clinical status.Kroll MH Archives of pathology & laboratory medicine (2010)
    2. [2]
    3. [3]
      The costing of tests in a laboratory for clinical chemistry and haematology.Leijten JF, van der Geer F, Scholten MN, Goldschmidt HM Annals of clinical biochemistry (1984)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG